Literature DB >> 19466960

Gene therapy of inherited skin adhesion disorders: a critical overview.

M De Luca1, G Pellegrini, F Mavilio.   

Abstract

Gene therapy has the potential to treat devastating inherited diseases for which there is little hope of finding a conventional cure. These include lethal diseases, like immunodeficiencies or several metabolic disorders, or conditions associated with a relatively long life expectancy but poor quality of life and expensive and life-long symptomatic treatments, such as muscular dystrophy, cystic fibrosis and thalassaemia. Skin adhesion defects belong to both groups. For the nonlethal forms, gene therapy, or transplantation of cultured skin derived from genetically corrected epidermal stem cells, represents a very attractive therapeutic option, and potentially a definitive treatment. Recent advances in gene transfer and stem cell culture technology are making this option closer than ever. This paper critically reviews the progress and prospects of gene therapy for epidermolysis bullosa, and the technical and nontechnical factors currently limiting its development.

Entities:  

Mesh:

Year:  2009        PMID: 19466960     DOI: 10.1111/j.1365-2133.2009.09243.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  22 in total

Review 1.  Induced pluripotent stem cells in dermatology: potentials, advances, and limitations.

Authors:  Ganna Bilousova; Dennis R Roop
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-03       Impact factor: 6.915

2.  Distinct strategies are required to suppress antigen-specific responses to genetically modified keratinocytes and fibroblasts.

Authors:  Soosan Ghazizadeh; Li T Huang; Weibing Zhang
Journal:  Mol Ther       Date:  2011-10-11       Impact factor: 11.454

3.  Ex-vivo gene therapy restores LEKTI activity and corrects the architecture of Netherton syndrome-derived skin grafts.

Authors:  Wei-Li Di; Fernado Larcher; Ekaterina Semenova; Gill E Talbot; John I Harper; Marcela Del Rio; Adrian J Thrasher; Waseem Qasim
Journal:  Mol Ther       Date:  2010-09-28       Impact factor: 11.454

4.  Superficial dermal fibroblasts enhance basement membrane and epidermal barrier formation in tissue-engineered skin: implications for treatment of skin basement membrane disorders.

Authors:  Mathew Varkey; Jie Ding; Edward E Tredget
Journal:  Tissue Eng Part A       Date:  2013-10-17       Impact factor: 3.845

Review 5.  Laminin 332 in junctional epidermolysis bullosa.

Authors:  Dimitra Kiritsi; Cristina Has; Leena Bruckner-Tuderman
Journal:  Cell Adh Migr       Date:  2012-10-17       Impact factor: 3.405

6.  Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy.

Authors:  Jessica Sallach; Giovanni Di Pasquale; Fernando Larcher; Nadine Niehoff; Matthias Rübsam; Anke Huber; Jay Chiorini; David Almarza; Sabine A Eming; Hikmet Ulus; Stephen Nishimura; Ulrich T Hacker; Michael Hallek; Carien M Niessen; Hildegard Büning
Journal:  Mol Ther       Date:  2014-01-28       Impact factor: 11.454

Review 7.  Gene therapy for skin diseases.

Authors:  Emily Gorell; Ngon Nguyen; Alfred Lane; Zurab Siprashvili
Journal:  Cold Spring Harb Perspect Med       Date:  2014-04-01       Impact factor: 6.915

8.  Induced pluripotent stem cells from individuals with recessive dystrophic epidermolysis bullosa.

Authors:  Jakub Tolar; Lily Xia; Megan J Riddle; Chris J Lees; Cindy R Eide; Ron T McElmurry; Matthias Titeux; Mark J Osborn; Troy C Lund; Alain Hovnanian; John E Wagner; Bruce R Blazar
Journal:  J Invest Dermatol       Date:  2010-12-02       Impact factor: 8.551

Review 9.  Allogeneic blood and bone marrow cells for the treatment of severe epidermolysis bullosa: repair of the extracellular matrix.

Authors:  Jakub Tolar; John E Wagner
Journal:  Lancet       Date:  2013-10-05       Impact factor: 79.321

Review 10.  Molecular therapeutics for heritable skin diseases.

Authors:  Jouni Uitto
Journal:  J Invest Dermatol       Date:  2012-11-15       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.